# FDA Approves Vepdegestrant (Veppanu), First PROTAC Therapy for ESR1-Mutated Metastatic Breast Cancer

> fda · REPORTED · 2026-08-05

The FDA recently approved vepdegestrant (Veppanu), the first PROTAC-based therapy approved for breast cancer, targeting ESR1-mutated hormone receptor-positive metastatic breast cancer. The approval marks a new mechanistic class entering breast cancer treatment and represents a significant milestone in precision oncology for women with endocrine-resistant disease.

About Pfizer / Arvinas (Vepdegestrant): Vepdegestrant (Veppanu) is a first-in-class oral PROTAC estrogen receptor degrader co-developed by Arvinas and Pfizer, designed to selectively degrade the estrogen receptor in ESR1-mutated breast cancer cells to overcome resistance to standard endocrine therapies.

- Company: Pfizer / Arvinas (Vepdegestrant)
- Sector: oncology
- Primary source: https://www.oncnursingnews.com/view/vepdegestrant-fda-approval-what-to-know-about-the-first-breast-cancer-protac

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.